Needham & Company Reiterates Buy on Alnylam Pharmaceuticals (ALNY), Says Stock Undervalued

Needham & Company reiterated their Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) and price target of $20.00.

Alnylam management reviewed 2Q12 in a conference call after market close yesterday. During the call, they announced new preclinical data supporting feasibility of subcutaneous administration of RNAi. Given the encouraging data, management guided for ALN-TTRsc IND submission in 2H12 and ALN-AT3 IND submission in 2013, said analyst Alan Carr in a research note today.

"Overall, we are impressed by the consistency in safety, PK, and efficacy profiles of the company’s candidates across preclinical models and in human trials. We believe the stock is undervalued," added Carr.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $18.44 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
• Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
• Needham & Company reiterates Buy rating on Amazon (AMZN), raises estimates